Instylla Announces Daniel Davis as New Board Member
Instylla, Inc., a clinical-stage company developing cutting-edge solutions for peripheral vascular embolization, has recently appointed Daniel Davis to its Board of Directors. This key decision is expected to further strengthen the company's leadership as it progresses with its innovative medical devices.
Daniel Davis's Experience and Background
Daniel Davis brings over 25 years of extensive experience in the medical device industry. He currently serves as the Chief Strategy Officer at Imperative Care, where he has significantly contributed to the growth and strategic initiatives related to stroke and vascular technologies. His previous roles include serving as Chief Commercial Officer and President for North America at Penumbra, Inc., where he was pivotal in the commercialization efforts of embolization and thrombectomy technologies targeting neurovascular and peripheral vascular applications.
A Warm Welcome to the New Board Member
Amar Sawhney, Chairman and CEO of Instylla, expressed enthusiasm about Daniel's addition to the Board. Amar stated, "We are very pleased to welcome Daniel Davis to the Board at Instylla. His incisive leadership and extensive industry insights align perfectly with our objectives as we work towards the commercialization of our next-generation liquid embolics."
Daniel's Vision for Instylla
Daniel Davis conveyed his excitement about joining the Board at such a transformative time in the company’s trajectory, mentioning, "Instylla has brought forward innovations that have the potential to transform treatment and outcomes, and I am honored to join Amar and the leadership team at this exciting time in the company's growth." He also noted the importance of advancing the Embrace™ Hydrogel Embolic System and bringing the Tembo™ Embolic System to market effectively.
About Instylla, Inc.
Instylla, Inc. was founded in 2017 and is dedicated to developing novel resorbable embolic agents aimed at improving interventional radiology procedures. With a focus on clinical applications in interventional oncology and peripheral vasculature, Instylla strives to create solutions that enhance treatment efficacy. Being a privately held company based in Bedford, MA, it is backed by numerous leading venture capital groups, ensuring solid financial support for its innovative projects.
Future Aspirations of Instylla
The company is on the cutting edge of advancing its medical technologies, aiming to revolutionize the field of interventional radiology. With innovative products like the Embrace™ Hydrogel Embolic System, Instylla is poised to make a significant impact on patient care and treatment outcomes. The leadership team's commitment to combining vast experience and visionary strategies will guide the company as it navigates its exciting journey ahead.
Frequently Asked Questions
Who is Daniel Davis?
Daniel Davis is the newly appointed Board Member at Instylla, bringing over 25 years of experience in the medical device industry.
What role does Daniel Davis hold at Imperative Care?
Daniel is currently the Chief Strategy Officer at Imperative Care, focusing on growth and strategic initiatives in vascular technologies.
What is Instylla, Inc. known for?
Instylla is a clinical-stage company specializing in developing innovative embolic agents for interventional radiology.
What products is Instylla currently focusing on?
Instylla is focused on advancing the Embrace™ Hydrogel Embolic System and the Tembo™ Embolic System.
When was Instylla founded?
Instylla was founded in 2017 and has been dedicated to developing innovative healthcare solutions since its inception.